🇺🇸 FDA
Patent

US 11708415

Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1

granted A61KA61K2039/507A61P

Quick answer

US patent 11708415 (Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/507, A61P, A61P11/00, A61P11/06